Financial Data and Key Metrics Changes - The overall net operating income (NOI) for the fourth quarter of 2025 was $10.9 million, an increase from $7 million in the prior quarter [10] - Core Funds from Operations (FFO) was negative $5.9 million, compared to negative $7 million in the prior year [24] - The company reported a negative FFO of $7.1 million, or negative $4.49 per diluted share, an improvement from negative $8.7 million, or negative $23.21 per diluted share in the prior year [23] Business Line Data and Key Metrics Changes - Office segment NOI for Q4 2025 was $6.4 million, up from $5.2 million during Q4 2024, driven by increased occupancy and rental rates in properties located in Austin and Beverly Hills [19][20] - Hotel segment NOI for Q4 2025 was $2.1 million, consistent with the prior year [21] - Multifamily segment NOI decreased to a loss of $870,000 during Q4 2025, compared to income of $855,000 in the prior year, primarily due to unrealized losses on investments [21] Market Data and Key Metrics Changes - In Oakland, the vacancy rate declined to 8% from a high of 18% in 2001, with rent growth turning positive in 2025 after three years of declines [16] - The office segment occupancy rate reached 88.5% at the end of 2025, a 190 basis point increase from the third quarter and a 680 basis point improvement year-over-year [8][17] Company Strategy and Development Direction - The company is focusing on premier multifamily assets, strengthening its balance sheet, and improving liquidity [4] - The company completed the sale of its lending division for approximately $44.9 million, generating about $31.2 million in net cash proceeds [6][7] - The company plans to redeem approximately 2 million shares of Series A preferred stock, which is expected to improve annual FFO by approximately $16 million [5] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about improving cash flow in 2026, supported by rising net operating income across all segments [8] - The company anticipates lower interest expenses due to a potentially more favorable rate environment and plans to refinance the hotel following renovations [9] - Management noted that the company does not currently intend to initiate additional preferred stock redemptions but will evaluate requests as they arise [6] Other Important Information - The company has completed nine refinancings and fully retired its $169 million recourse credit facility [12] - The company is working on the extension of two more assets expected to be completed in Q2 2026 [12] Q&A Session Summary Question: What are the expectations for future cash flow improvements? - Management indicated that they see opportunities to improve cash flow in 2026, supported by several key drivers across the portfolio [8] Question: How is the company addressing its preferred stock redemptions? - Management stated that they do not currently intend to initiate additional preferred stock redemptions but will evaluate requests as they come in [6] Question: What is the status of the hotel renovations? - Management confirmed that the renovations at the Sheraton Grand Sacramento have been substantially completed and are expected to positively impact profitability [18]

Financial Data and Key Metrics Changes - In Q4 2025, REPAY achieved revenue of $78.6 million, reflecting a 10% normalized year-over-year growth, while gross profit was $58.3 million, with a 9% growth on a normalized basis [13][14] - Adjusted EBITDA margins were approximately 41%, and free cash flow conversion was 43% [5][14] - Reported net income was impacted by a non-cash goodwill impairment charge of $138.9 million related to the consumer payments segment [14] Business Line Data and Key Metrics Changes - Consumer payments segment saw revenue increase of 8% and gross profit increase of 6% year-over-year [5][14] - Business payments segment experienced a significant increase, with normalized revenue up 41% and gross profit up 73% year-over-year [7][14] Market Data and Key Metrics Changes - The supplier network in the business payments segment grew to 602,000 suppliers, an increase of over 65% year-over-year [8] - The company added 14 software partners and integrations during 2025, exiting the year with over 294 total partners [9] Company Strategy and Development Direction - REPAY is focused on improving operations, go-to-market strategies, and overall organizational leadership to support growth in 2026 [4] - The company plans to allocate capital towards organic growth opportunities, strategic M&A, and partnerships to enhance long-term growth and cash flow [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a revenue target of $340 million to $346 million for 2026, representing 10%-12% reported revenue growth [17] - The company anticipates a strong midterm election cycle to positively impact revenue by $8 million-$10 million, contributing approximately 3 percentage points of reported growth year-over-year [19] Other Important Information - REPAY's pro forma total liquidity is approximately $219 million, which includes $140 million of undrawn revolver capacity [16] - The company is committed to implementing its capital allocation strategy to achieve double-digit reported growth and strong profitability in 2026 [22] Q&A Session Summary Question: Insights on major end markets like auto, personal loans, healthcare, and mortgage - Management noted stable trends in auto and personal loans, with no significant changes observed in healthcare or mortgage markets [25][26] Question: Impact of tax refunds on volumes and repayment activity - Management indicated a seasonal uplift in payment volume related to tax refunds, consistent with previous years [31] Question: Contribution of float income to growth and margins - Float income from customer deposits in the B2B business played a significant role in Q4 results, with stable contributions expected moving forward [32][33] Question: Update on M&A pipeline and focus on consumer vs. business payments - Management confirmed a healthy pipeline for potential M&A opportunities in both consumer and business payments, focusing on selective investments [37] Question: Growth expectations for the business payment segment - Management anticipates high teens growth for the business payments segment, influenced by the political year and expected revenue contributions from political media [49][50]

Financial Data and Key Metrics Changes - Total net revenue for Q2 declined approximately 5% year-over-year, primarily due to unfavorable weather conditions impacting visitation and ancillary spending [15][17] - Resort Reported EBITDA decreased approximately 8% compared to the prior year, with Rockies snowfall down 43% year-over-year [15][17] - Skier visitation declined approximately 12% season-to-date, with lift revenue down approximately 4% [16][17] Business Line Data and Key Metrics Changes - Total Q2 lift revenue declined approximately 3%, despite visitation being down 13%, reflecting stability from pass sales which were up approximately 3% [15][16] - Ancillary revenue trends improved compared to January metrics but remained down versus the prior year due to lower visitation [16] Market Data and Key Metrics Changes - Conditions in the Rockies were the most challenging, with snowfall at historic lows, while conditions in the East were strong, providing a partial offset [15][16] - The company noted that geographic diversification has historically provided support, although less evident this year due to severe conditions in the Rockies [7][15] Company Strategy and Development Direction - The company is focused on optimizing visitation through enhanced marketing initiatives and new products, including a new pricing strategy for young adults [8][9] - A commitment to geographic diversification and advanced commitment strategies has been emphasized to mitigate regional weather impacts [6][7] - The company plans to continue investing in technology and guest-facing improvements to enhance the overall experience [13][21] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the unprecedented weather challenges and their impact on performance, but expressed confidence in the resilience of the business model [5][12] - The updated fiscal 2026 guidance reflects reduced expectations for net income and Resort Reported EBITDA due to ongoing weather conditions [17][18] - Management remains optimistic about the long-term value creation potential despite the current challenges [22][23] Other Important Information - The company has a strong balance sheet with approximately $1.1 billion in liquidity and a net leverage of 3.1x trailing 12 months EBITDA [19] - Capital expenditures for fiscal 2026 are reaffirmed at $215 million-$220 million, with a focus on technology investments [21] Q&A Session Summary Question: Impact of weather on next season's renewals - Management noted that historical patterns suggest that customers tend to view poor weather years as anomalies and remain engaged with the sport [26][27] Question: Flow-through assumptions regarding revenue and EBITDA - Management explained that the high flow-through is due to fixed costs and the need to maintain guest experience despite lower visitation [30] Question: Marketing efforts and social presence feedback - Management highlighted positive results from enhanced marketing strategies, particularly in social media, which have driven pass sales [34][35] Question: Future capital expenditures for snowmaking - Management confirmed a long-term commitment to upgrading snowmaking systems but noted that decisions for capital investments are made based on prior season results [45][46] Question: Proactive actions to accelerate visitation - Management reported positive traction from new ticket initiatives and pricing strategies, indicating potential for future growth despite current weather challenges [50][51] Question: Pricing strategy for young adults - Management discussed the rationale behind the 20% discount for young adults, emphasizing the importance of engaging this demographic for long-term growth [90][91]

Financial Data and Key Metrics Changes - Total net revenue declined approximately 5% in Q2 2026 compared to the prior year, primarily due to unfavorable weather conditions impacting visitation and ancillary spending [13][14] - Resort Reported EBITDA decreased approximately 8% year-over-year, with Rockies snowfall down 43% [13][15] - Skier visitation declined approximately 12% season-to-date, with lift revenue down approximately 4% [15][16] Business Line Data and Key Metrics Changes - Lift revenue declined approximately 3% in Q2 despite visitation being down 13%, reflecting stability from pass sales which were up approximately 3% [14][15] - Ancillary revenue trends improved compared to January metrics but remained down versus the prior year due to lower visitation [15] Market Data and Key Metrics Changes - Conditions in the Rockies were the most challenging on record, with snowfall and snowpack at historic lows, impacting overall performance [4][5] - Conditions in Whistler and Tahoe were variable, while the East experienced strong conditions, providing a partial offset to the Rockies' performance [13] Company Strategy and Development Direction - The company is focusing on geographic diversification to mitigate regional weather impacts, which has provided some support despite the severity of current conditions [6] - New pricing strategies were introduced for skiers and riders ages 13 to 30, offering a 20% discount to attract younger, price-sensitive customers [7][8] - The company is committed to enhancing marketing initiatives and product offerings to optimize visitation and drive revenue growth [6][9] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the unprecedented weather challenges and their impact on performance, but emphasized the resilience of the business model and the importance of the advanced commitment strategy [11][20] - The company expects to reduce fiscal 2026 net income guidance to a range of $144 million to $190 million, and Resort Reported EBITDA to $745 million to $775 million due to ongoing weather challenges [16][17] - Management remains confident in the strength of cash flow generation and the stability of the business model despite the difficult operating environment [18][21] Other Important Information - The company retired $525 million of convertible debt and amended its credit agreement to extend the maturity date to 2031 [18][19] - The quarterly dividend was maintained at $2.22 per share, with a focus on reinvestment and capital allocation flexibility [19][20] Q&A Session Summary Question: How will this season's weather impact renewals for next year? - Management believes that while weather conditions may affect immediate renewals, historical patterns show that customers remain engaged with the sport despite challenging seasons [25][26] Question: Can you explain the high flow-through assumption in your model? - Management indicated that the high flow-through is due to fixed costs and the need to maintain high guest experience levels despite revenue impacts from weather [28][29] Question: What feedback have you received on your marketing efforts? - Management noted positive results from social media and influencer campaigns, which have driven pass sales and engagement [34][35] Question: Will there be significant CapEx for snowmaking after this season? - Management confirmed ongoing investments in snowmaking as part of their long-term strategy, but specific plans for post-season investments are not yet finalized [44][45] Question: How do you view the impact of the young adult discount program? - Management sees the program as a way to engage younger customers and believes it will lead to increased participation in the sport [66][68] Question: What factors are driving variability in your guidance? - Management highlighted that the current low snowpack creates greater uncertainty for the remainder of the season, impacting guidance variability [69][70]

Financial Data and Key Metrics Changes - In Q4 2025, the company achieved 10% revenue growth and 9% gross profit growth on a normalized year-over-year basis, excluding political media contributions from 2024 [5][14] - Adjusted EBITDA margins were 41%, and free cash flow conversion was 43% [5][15] - Q4 revenue was $78.6 million, and gross profit was $58.3 million, with gross profit margins at approximately 74.2% [13][14] Business Line Data and Key Metrics Changes - In the consumer payment segment, Q4 revenue increased by 8% and gross profit increased by 6% year-over-year [5][14] - The business payments segment saw normalized revenue increase by 41% and gross profit increase by 73% year-over-year [7][14] - The supplier network in the business payments segment grew to 602,000 suppliers, a 65% increase year-over-year [8] Market Data and Key Metrics Changes - The company noted stable trends in the auto and personal loans markets, with no significant changes reported in healthcare or mortgage sectors [26][27] - The political media contributions are expected to positively impact revenue by $8 million to $10 million in 2026, contributing approximately 3 percentage points to reported growth year-over-year [20] Company Strategy and Development Direction - The company is focused on improving operations, go-to-market strategies, and overall organizational leadership to support growth in 2026 [4][10] - Strategic changes in 2025 included executive changes, process streamlining, and investments in automation and AI to enhance operational efficiency [10][11] - The company plans to allocate capital towards organic growth opportunities, strategic M&A, and partnerships to boost long-term growth [21][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving double-digit reported revenue growth in 2026, driven by existing client growth and new client ramp-up [18][22] - The first quarter of 2026 is expected to show lower year-over-year growth due to delayed client implementations, with a return to strong double-digit normalized growth anticipated in the second half of the year [20][22] - The company is positioned to leverage AI capabilities to enhance productivity and streamline client onboarding processes [11][12] Other Important Information - The company ended 2025 with approximately $116 million in cash and a pro forma total liquidity of about $219 million [16][17] - The company has $23 million remaining under its existing share repurchase program for 2026 [21] Q&A Session Summary Question: Insights on major end markets like auto, personal loans, healthcare, and mortgage - Management noted stable trends in auto and personal loans, with no significant changes in healthcare or mortgage markets [26][27] Question: Any upcoming customer renewals in 2026 - Management indicated no major renewals outside of standard auto-renewals that are already embedded in guidance [28] Question: Impact of tax refunds on volumes and repayment activity - Management observed a seasonal uplift in payment volume during tax refund season, consistent with previous years [32][33] Question: Contribution of float income to growth and margins - Float income from customer deposits in the B2B business contributed positively to fourth-quarter results, with stable expectations for 2026 [34][35] Question: Update on M&A pipeline and focus areas - Management confirmed a healthy M&A pipeline with opportunities in both consumer and business payments, focusing on partnerships that complement existing business units [39] Question: Growth expectations for the business payment segment - Management anticipates high teens growth for the business payments segment, influenced by the political year and expected contributions from political media [52][53]

Financial Data and Key Metrics Changes - The company's overall net operating income (NOI) for Q4 2025 was $10.9 million, an increase from $7 million in the prior quarter [10] - Core Funds from Operations (FFO) was negative $5.9 million, compared to negative $7 million in the prior year [24] - The overall FFO was negative $7.1 million, or negative $4.49 per diluted share, an improvement from negative $8.7 million, or negative $23.21 per diluted share in the prior year [23][24] Business Line Data and Key Metrics Changes - Office segment NOI increased to $6.4 million in Q4 2025 from $5.2 million in Q4 2024, driven by higher occupancy and rental rates [20][21] - Hotel segment NOI for Q4 2025 was $2.1 million, consistent with the prior year [22] - Multifamily segment NOI decreased to a loss of $870,000 in Q4 2025, compared to income of $855,000 in the prior year, primarily due to unrealized losses on investments [22] Market Data and Key Metrics Changes - In Oakland, multifamily occupancy improved to 88.4% at year-end 2025, a 370 basis point increase from the end of Q3 2025 [17] - The office segment occupancy reached 88.5% at the end of 2025, a 190 basis point improvement from Q3 2025 and a 680 basis point improvement year-over-year [18] - Rent growth in downtown San Francisco was 7.6% in 2025, the highest in over 25 years, with the vacancy rate declining to its lowest levels in 15 years [16] Company Strategy and Development Direction - The company is focusing on premier multifamily assets, strengthening its balance sheet, and improving liquidity [4] - Actions taken since September 2024 include financing on nine assets and the sale of the lending division, which generated approximately $31.2 million in net cash proceeds [5][6] - The company plans to continue evaluating asset sales to enhance liquidity and optimize its balance sheet [7] Management's Comments on Operating Environment and Future Outlook - Management sees opportunities to improve cash flow in 2026, supported by improving net operating income across all segments [7] - The company anticipates lower interest expenses due to a potentially more favorable rate environment and plans to refinance the hotel following renovations [9] - Management expressed confidence in the strategic plan and the positive trends in operating performance across the portfolio [4] Other Important Information - The company is redeeming approximately 2 million shares of Series A preferred stock, which is expected to improve annual funds from operations by approximately $16 million [5] - The company has completed renovations at the Sheraton Grand Sacramento, which is expected to significantly impact profitability in 2026 [19] Q&A Session Summary - No specific questions and answers were provided in the content, thus this section is not applicable.

Financial Data and Key Metrics Changes - Q1 revenue was $9.3 billion, up 18% year-over-year, with record earnings per share of $0.65, exceeding the high end of the outlook [5][21] - Free cash flow for Q1 was $708 million, demonstrating strong cash management [20][29] - Gross margin improved to 36.6%, driven by pricing discipline and a favorable mix towards networking [21][25] Business Segment Data and Key Metrics Changes - Networking segment revenue increased 152% year-over-year, with normalized growth of 7%, representing nearly 30% of total revenues [9][22] - Cloud and AI segment revenue declined 3%, with operating margin dollars up 18%, driven by pricing and cost discipline [15][24] - Storage revenue was up 1%, with strong growth in Storage Alletra MP products, marking five consecutive quarters of double-digit growth [16][27] Market Data and Key Metrics Changes - Strong demand for networking products, particularly in wireless data center switching and routing, with orders growing mid-20% on a normalized basis [10][63] - AI systems backlog reached a record $5 billion, primarily from enterprise and sovereign orders [16][26] - The company expects higher average unit prices in server and storage products due to rising component costs, particularly in DRAM and NAND [8][25] Company Strategy and Development Direction - The integration of Juniper Networks is progressing well, with a focus on building a new networking market leader [6][14] - The company is prioritizing higher margin product orders in response to supply dynamics and inflationary pressures [8][33] - HPE aims to leverage its GreenLake platform to enhance customer adoption and drive subscription services [5][17] Management's Comments on Operating Environment and Future Outlook - Management noted significant commodity supply and cost headwinds, with expectations of elevated prices persisting into 2027 [6][31] - The company raised its fiscal 2026 EPS outlook to $2.30-$2.50, reflecting confidence in demand and operational execution [32][34] - Management emphasized strong customer demand despite rising prices, indicating no signs of demand destruction [41][54] Other Important Information - The company is on track to achieve its fiscal 2026 synergy targets from the Juniper integration [6][18] - HPEFS delivered record return on equity, highlighting the strategic advantage of financial services during high commodity cost cycles [17][27] - The company is actively managing its supply chain and pricing strategies to mitigate the impact of rising component costs [7][25] Q&A Session Summary Question: Will the current environment drive more customers to use HPE GreenLake? - Management confirmed that demand for GreenLake remains strong, with customers seeking flexible consumption models [40] Question: How are rising memory prices reflected in profitability outlook? - Management indicated that memory cost increases are expected to persist, but they have secured supply to meet guidance [44][46] Question: What is driving the uptick in networking growth expectations? - The increase is attributed to strong demand for products, particularly in AI and campus solutions, as well as successful integration with Juniper [59][63] Question: How does the company view demand elasticity in relation to price increases? - Management noted that demand remains strong, with customers willing to accept higher prices for faster delivery [52][54] Question: What is the mix between data center networking and routing in the networks for AI orders? - The growth in networks for AI orders is driven by both existing and new customers, with a strong pipeline supporting the raised outlook [85]

Financial Performance - In Q4 2025, total net revenue was $34.1 million, including $26.4 million from MIPLYFFA sales, $400,000 from OLPRUVA, $5.6 million from global EAP reimbursements, and $1.8 million from royalties under the AZSTARYS license [22][23] - For the full year 2025, net revenue reached $106.5 million, with $87.4 million from MIPLYFFA sales, $800,000 from OLPRUVA, $13 million from global EAP reimbursements, and $5 million from royalties [24] - Operating expenses for Q4 were $23 million, a decrease of $1.5 million year-over-year, while full-year operating expenses were $90.4 million, down $6.6 million from 2024 [22][24] - Net income for Q4 was $12.2 million, compared to a net loss of $35.7 million in Q4 2024, and full-year net income was $83.2 million, compared to a net loss of $105.5 million in 2024 [23][24] Business Line Performance - MIPLYFFA generated $87.4 million in revenue for the full year 2025, with strong commercial performance reflected in 52 prescription enrollment forms received in the first year of commercialization [5][6] - In Q4, 24 new prescription enrollment forms were received, contributing to a total of 161 enrollments since launch [6][14] - The company is expanding access to MIPLYFFA through a global expanded access program, with 113 patients enrolled by the end of 2025 [8] Market Data - The estimated U.S. prevalence of Niemann-Pick disease type C (NPC) is approximately 900 individuals, with 300-350 currently diagnosed [7] - In Europe, NPC prevalence is estimated at around 1,100 individuals, with the current EAP supporting nearly 10% of this population [9] - Diagnosis rates in Europe are higher due to the approval of miglustat, leading to stronger physician awareness and higher patient identification [10] Company Strategy and Industry Competition - The company aims to redefine therapies for rare diseases, focusing on patient-centricity, integrity, accountability, innovation, and courage [5] - MIPLYFFA has exclusivity in the U.S. through 2031 under the Orphan Drug Designation, and the company is pursuing a patent term extension [7] - The company is also advancing celiprolol for the treatment of vascular Ehlers-Danlos syndrome, with ongoing Phase III studies [10][11] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of MIPLYFFA, driven by both previously diagnosed and newly diagnosed patients [15][16] - The company is focused on expanding access and strengthening relationships with key opinion leaders to maximize commercial impact [10] - Management highlighted the importance of ongoing education and awareness campaigns to facilitate early diagnosis and treatment [16][18] Other Important Information - The company moved its headquarters to Boston to enhance collaboration and access to specialized talent [12][13] - The new CFO, Justin Renz, officially started on the call date and will support the company's long-term value creation [4][28] Q&A Session Summary Question: Can you provide details on the split of new diagnoses versus previously identified patients? - Management noted that there has been meaningful growth in newly diagnosed patients, attributed to clinical data strength and disease awareness campaigns [33][34] Question: What is the expected timeline for diagnosis confirmation? - Management indicated that the timeline for diagnosis can vary significantly due to the nature of rare diseases, but efforts are being made to streamline the process [37][40] Question: Can you discuss persistency rates for patients on therapy? - Management stated that it is too early to provide meaningful data on persistency but expressed encouragement from refill rates observed [45][46] Question: How is the initial experience with the Uniphar collaboration? - Management expressed satisfaction with the collaboration, noting that it has facilitated rapid product delivery to patients [47][48] Question: What is the expected growth of EAP revenue? - Management clarified that EAP revenue is based on individual patient shipments and will have variability quarter-over-quarter [54][55] Question: How is the gross to net evolving in the U.S.? - Management noted that gross to net has evolved and is dynamic, making it difficult to provide specific guidance [58] Question: What is the average age of patients on MIPLYFFA? - Management indicated that approximately half of MIPLYFFA patients are adults, reflecting the patient mix seen in the expanded access program [64][66] Question: What are the next steps for the EMA application? - Management confirmed readiness to respond to the EMA's questions and emphasized the robustness of the data package submitted [69]

Financial Data and Key Metrics Changes - The company reported full-year revenue of $40.9 million, representing a 26% growth over 2024 [5][21] - Fourth quarter revenue was $11.4 million, the highest revenue quarter of the year, up 13% from the third quarter but down slightly year-over-year [15][19] - Gross margin for the fourth quarter was 68.6%, down from 71.4% a year ago, but up from 63.8% in the third quarter [19][21] - Operating loss for the fourth quarter was $2.8 million, compared to an operating loss of about $200,000 in the prior year quarter [20][21] - Net loss for the fourth quarter was $3.8 million, or $0.09 per share, compared to a net loss of $300,000 or $0.01 per share for the same quarter last year [20][21] Business Line Data and Key Metrics Changes - The U.S. Orthotics and Prosthetics (O&P) channel achieved quarterly revenue exceeding $1 million for the first time, up 81% year-over-year [7][18] - International revenue reached a record $2.2 million, up 46% year-over-year, representing 19% of total revenue [18] - The company recorded 241 MyoPros ordered during the fourth quarter, up 5% sequentially from the third quarter [5][19] - Recurring patient sources, including referrals under the MyoConnect program, represented 42% of fourth quarter revenue, up from 26% in the fourth quarter of 2024 [8][18] Market Data and Key Metrics Changes - The company signed in-network contracts with additional Medicare Advantage and commercial payers, including a multi-state agreement with Elevance Health covering 45 million lives [10][11] - The patient pipeline stood at 1,528 patients as of December 31, 2025, an increase of 10% year-over-year [18] - The company faced challenges with Medicare Advantage payers, which issued a high number of pre-authorization denials [16][17] Company Strategy and Development Direction - The company aims to grow revenue through direct-to-patient marketing and expand orders from recurring sources [4] - A strategic pivot towards recurring patient sources is evident, with a focus on the MyoConnect program to engage therapists and physicians [8][12] - The company plans to limit advertising spending while building out the MyoConnect program and adding direct sales resources [23] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in the O&P channel and international markets, despite challenges with Medicare Advantage [10][17] - The company expects revenue in 2026 to be in the range of $43 million to $46 million, with a focus on recurring sources [23][24] - Management anticipates a reduction in cash burn by roughly half in 2026 compared to 2025 [24] Other Important Information - The company launched the MyoPro Center of Excellence program to educate O&P practices on the new MyoPro 2X product [6] - A randomized controlled trial is being conducted to further validate the MyoPro's effectiveness, with results expected by the end of the year [79] Q&A Session Summary Question: What drove the increase in cost per pipeline ad in the MyoConnect program? - Management noted that the fourth quarter typically has higher advertising costs due to competition and that a new marketing head and agency have been brought on to address this [34][35] Question: Can you provide KPIs around the O&P channel? - The company has trained and certified a couple of dozen O&P providers, generating over $1 million in revenue in the quarter [38][39] Question: What are the assumptions for the U.S. O&P business in 2026 guidance? - Growth is expected in the O&P channel and international markets, while direct billing is anticipated to remain flat [41][42] Question: What is the status of the pipeline ads and dropout rate? - The pipeline ads were lower due to a shutdown in late December, and the dropout rate was noted to be around 20% [46][50] Question: How is the German market performing? - The German market is growing well due to favorable reimbursement policies and a strong recruitment of O&P practices [78] Question: What is the timeline for the MyoPro 3 model? - The MyoPro 3 will be a next-generation platform with significant improvements, but specific timelines were not provided [81]

Financial Data and Key Metrics Changes - Coherus Oncology reported a net revenue of $40.8 million for the full year 2025, representing a 113% growth year-over-year compared to $19.1 million in 2024 [28] - For Q4 2025, net revenue was $12.4 million, reflecting an 11% growth over Q3 2025, with a strong quarter-over-quarter demand growth of 15.5% in Q4 [28] - The company reduced its secured and convertible debt by over 90% from $480 million to $38.8 million by the end of 2025, significantly lowering interest costs [34][38] Business Line Data and Key Metrics Changes - LOQTORZI, the company's first innovative oncology commercial product, more than doubled its sales in 2025 compared to 2024, with expectations of continued growth driven by new patient starts and increased market penetration [6][28] - The company anticipates achieving peak market share for LOQTORZI by 2028, targeting $175 million in annualized revenues, which would represent about 70% market share of the $250 million total addressable market [7][32] Market Data and Key Metrics Changes - The NCCN guidelines for nasopharyngeal carcinoma (NPC) were updated in late 2024, positioning LOQTORZI as the only preferred treatment for recurrent and metastatic NPC, which has stimulated growth in 2025 [29] - The company is focusing on expanding its reach in the community segment, where off-label immuno-oncology (IO) treatments persist [29] Company Strategy and Development Direction - Coherus has transitioned from a biosimilar company to an innovative oncology company, focusing on overcoming immune resistance in cancer through strategic acquisitions and product development [4][6] - The company is investing in its pipeline, particularly in tagmokitug and Casdozokitug, with multiple clinical readouts expected in 2026 [10][27] - The strategic partnership with Johnson & Johnson for tagmokitug is seen as a validation of the company's scientific competency and a pathway to further collaborations [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in LOQTORZI's growth trajectory, supported by strong clinical data showing significant survival benefits compared to chemotherapy alone [30] - The company is well-positioned financially, with sufficient funding to support operations and pipeline advancements through 2026 and into 2027 [9][39] - Management highlighted the importance of educating oncologists on the new survival data to drive adoption of LOQTORZI [30] Other Important Information - The company has reduced its headcount from approximately 228 at the end of 2024 to about 147 at the end of 2025, reflecting a 35% reduction [34] - Coherus is eligible for two earn-out sales milestones of $37.5 million each based on UDENYCA sales performance, which could provide additional financial support [36] Q&A Session Summary Question: Can you provide more color on the dynamic between new patient starts and repeat patients in 2025? - Approximately 25% of the business came from new patients in 2025, with expectations that this mix will shift slightly more towards new patients in 2026 as the duration of therapy for existing patients increases [46] Question: What are the promotional sensitivities of LOQTORZI? - LOQTORZI is highly promotion sensitive, requiring continuous reminders to physicians about its benefits due to the rarity of NPC cases [49] Question: Can you discuss the additional investments in commercial infrastructure? - The company has expanded its field force by 15% and added inside sales representatives to target tier 2 accounts, along with investments in IT infrastructure to capture patient opportunities [51][52] Question: What are the plans for exploring a triple combination with TAGMO? - The initial step will be to evaluate the combination of tagmokitug and pasritamig before considering additional combinations [57] Question: How will data from ongoing trials be disclosed? - Data will be reported as it becomes available, either aligned with congress submission deadlines or through corporate disclosures [62]